Kosin Med J.  2017 Jun;32(1):25-35. 10.7180/kmj.2017.32.1.25.

Effect of Rheumatoid Factor on Vascular Stiffness in General Population without Joint Symptoms

• Lee JH
• Tag HS
• Kim GT
• Kim MJ
• Lee SG
• Park EK
• Koo DW

• KMID: 2384831
• DOI: http://doi.org/10.7180/kmj.2017.32.1.25

Abstract

OBJECTIVES
The role of rheumatoid factor (RF) in vascular stiffness and cardiovascular risk in subjects without joint symptoms remains unclear. We investigated vascular stiffness in subjects without joint symptoms using pulse wave velocity (PWV), calculated Framingham risk scores (FRS), an estimator of cardiovascular risk, and analyzed whether vascular stiffness and FRS were affected by RF.
METHODS
Two hundred forty-two subjects were included in this population-based study. RF was quantified with turbid immunometry using a cut-off of RF > 15 IU/ml to denote RF positivity. Information was then obtained on joint symptoms. Brachial-ankle PWV (baPWV) was measured using an automated device.
RESULTS
Of the 242 subjects, 15 were RF-positive. RF-positive subjects without joint symptoms had a higher baPWV and FRS than RF-negative subjects without joint symptoms, but the difference did not reach statistical significance. However, when we stratified the subjects into two groups (group A - high RF: RF ≥ 40 IU/ml; group B - low RF: RF < 40 IU/ml), group A showed significantly higher baPWV (1640.7 ± 179.6 ㎝/s vs. 1405.7 ± 225.7 ㎝/s, P = 0.008) and FRS (25.7 ± 4.87 vs. 11.8 ± 9.6, P < 0.001). Multiple regression analysis was used to examine potential confounders, and RF exhibited significant but modest effects on baPWV (adjusted R-squared = 0.038, P = 0.030).
CONCLUSIONS
In a sample of the general population without joint symptoms, higher levels of RF were associated with increased vascular stiffness, suggesting a pathophysiologic link between RF and endothelial dysfunction.

Keyword

Pulse wave analysis; Rheumatoid factor; Vascular stiffness

MeSH Terms

Joints*
Pulse Wave Analysis
Rheumatoid Factor*
Vascular Stiffness*
Rheumatoid Factor

Figure

• 

  Fig. 1. Study population flowchart.

Reference

1.Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010. 36:405–26.

2.Aviña-Zubieta JA., Choi HK., Sadatsafavi M., Etminan M., Esdaile JM., Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008. 59:1690–7.

3.Goodson NJ., Wiles NJ., Lunt M., Barrett EM., Silman AJ., Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002. 46:2010–9.

4.del Rincon ID., Williams K., Stern MP., Freeman GL., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001. 44:2737–45.

5.Tomasson G., Aspelund T., Jonsson T., Valdimarsson H., Felson DT., Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis. 2010. 69:1649–54.

6.Gerli R., Bartoloni Bocci E., Sherer Y., Vaudo G., Moscatelli S., Shoenfeld T. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008. 67:724–5.

7.Lopez-Longo FJ., Oliver-Miňarro D., de la Torre I., González-Diáz de Rabago E., Sánchez-Ramón S., Rodriquez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009. 61:419–24.

8.Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol. 2000. 27:630–7.

9.Danesh J., Wheeler JG., Hirschfield GM., Eda S., Eiriksdottir G., Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004. 350:1387–97.

10.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel Ⅲ). JAMA. 2001. 285:2486–97.

11.Wilson PW., D'Agostino RB., Levy D., Belanger AM., Silbershatz H., Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998. 97:1837–47.

12.Marc CH., Alan JS., Josef SS., Michal EW., Michael HW. Rheumatology. 5th ed. p.887–95. London, Mosby. 2011.

13.Jansen AL., van der Horst-Bruinsma I., van Schaardenburg D., Van der Stadt RJ., de Koning MH., Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheum. 2002. 29:2074–6.

14.Nell VP., Machold KP., Stamm TA., Eberl G., Heinzl H., Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005. 64:1731–6.

15.Tomiyama H., Yamashina A., Arai T., Hirose K., Koji Y., Chikamori T, et al. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement -- a survey of 12517 subjects. Atherosclerosis. 2003. 166:303–9.

16.Lee JH., Cho KI., Kim SM. Carotid arterial stiffness in patients with rheumatoid arthritis assessed by speckle tracking strain imaging: its association with carotid atherosclerosis. Clin Exp Rheumatol. 2012. 30:720–8.

17.Gonzalez A., Icen M., Kremers HM., Crowson CS., Davis JM 3rd., Therneau TM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J rheumatol. 2008. 35:1009–14.

18.van Schaardenburg D., Hazes JM., de Boer A., Zwinderman AH., Meijers KA., Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol. 1993. 20:45–52.

19.Heliövaara M., Aho K., Knekt P., Aromaa A., Maatela J., Reunanen A. Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis. 1995. 54:811–4.

20.Boutouyrie P., Tropeano AI., Asmar R., Gautier I., Benetos A., Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002. 39:10–5.

21.Tomiyama H., Koji Y., Yambe M., Shiina K., Motobe K., Yamada J, et al. Brachial--ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J. 2005. 69:815–22.

22.Rhee MY., Lee HY., Park JB. Measurements of arterial stiffness: methodological aspects. Korean Circ J. 2008. 38:343–50.

23.Marc CH., Alan JS., Josef SS., Michal EW., Michael HW. Rheumatology. 5th ed. p.887–95. London, Mosby. 2011.

24.Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol. 2000. 27:630–7.

25.Libby P. Inflammation in atherosclerosis. Nature. 2002. 420:868–74.

26.Wick G., Knoflach M., Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004. 22:361–403.

27.Paoletti R., Gotto AM Jr., Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004. 109:Ⅲ. 20–6.

28.Kato H., Yamakawa M., Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol. 2000. 27:1839–47.